{
    "cancelStatus": "0",
    "cancelDate": null,
    "cancelReason": [],
    "licid": "51061123",
    "validDate": "2027-06-07 00:00:00.000",
    "issueDate": "2022-06-07 00:00:00.000",
    "licKind": "02",
    "oldLicid": null,
    "certNo": "DHY05106112300",
    "prodNameC": "\"霖揚\"愛萊諾迪肯注射液20毫克\/毫升",
    "prodNameE": "Irinotecan Injection 20mg\/mL \"GBC\"",
    "indicationsName": [
        "晚期性大腸直腸癌之第一線治療藥物：• 與5-FU及Folinic acid合併，使用於未曾接受過化學治療之患者。• 單獨使用於曾接受5-FU療程治療無效之患者。• 與cetuximab併用，治療曾接受含irinotecan之細胞毒性療法治療失敗且具有上皮生長因子接受體（EGFR）表現型KRAS野生型轉移性大腸直腸癌患者。• 與5-fluorouracil、folinic acid及bevacizumab合併治療，做為轉移性大腸癌或直腸癌患者的第一線治療藥物。• 與capecitabine合併治療，做為轉移性大腸直腸癌患者的第一線治療藥物。• 與5-fluorouracil、leucovorin及oxaliplatin合併治療（FOLFIRINOX），做為轉移性胰臟癌之第一線治療藥物。"
    ],
    "does": "227D",
    "packageUnit": [
        {
            "packageSpec": "2毫升、10毫升玻璃注射瓶裝",
            "packageUnit": ""
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "B",
    "ingredientsDesc": [
        "IRINOTECAN HYDROCHLORIDE TRIHYDRATE"
    ],
    "restraintItemsCode": [
        "01",
        "24"
    ],
    "applicantName": "霖揚生技製藥股份有限公司",
    "applicantAddr": "苗栗縣竹南鎮頂埔里科研路50-3號4樓、50-5號4樓、50-8號3樓、50-8號4樓、50-8號5樓、50-9號5樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": null,
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "factoryCode": "1",
            "factoryName": "霖揚生技製藥股份有限公司",
            "factoryAddr": "苗栗縣竹南鎮頂埔里科研路50-3號4樓、50-5號4樓、50-8號3樓、50-8號4樓、50-8號5樓、50-9號5樓",
            "factoryCompanyAddr": "",
            "countryCode": "TW",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "6135041295",
            "factoryInfo": null,
            "qsd": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "9200037710",
            "ingredientsDesc": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
            "concentDesc": "(Irinotecan Hydrochloride Trihydrate 20mg is equivalent to Irinotecan 17.33mg)",
            "concent": "20.000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01CE02"
        }
    ],
    "licBaseId": "9654911B-7AA9-417E-A0B6-DA2A46C3705B"
}